Now, a study led by the University of Barcelona confirms the therapeutic efficiency of a new compound against psoriasis, which could avoid the risks associated with previously known therapies. The stu...
Read moreThe study, published in JACC: CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves mitochondrial function, improves myocardial ener...
Read moreIt has benn described 25 new mouse models that recapitulate the main subtypes of hepatocellular carcinoma and allow personalised therapies to be tested. The potential of these models has been demonstr...
Read moreUn reciente estudio publicado en Frontiers in Psychiatry liderado por personal de varias áras del CIBER, demuestra la relación entre antidepresivos e incremento de peso. Gracias a los datos de segui...
Read moreImprovements in fibrosis observed using 3 pre-specified methods of histological analysis: conventional, AIM-MASH (PathAI) and qFibrosis (Histoindex)
Read moreEste estudio muestra por primera vez cómo un tipo de medicamento para la diabetes, llamado inhibidor del cotransportador de sodio-glucosa tipo 2 (SGLT2i), puede ayudar a proteger el corazón durante ...
Read moreResearchers from Clínic-IDIBAPS have participated in an international study published in The New England Journal of Medicine (NEJM), which demonstrates that tezepelumab, a biological drug, significan...
Read moreThe DapaTAVI study, conducted in 39 Spanish hospitals and coordinated by the CNIC, marks a breakthrough in cardiovascular research and could transform the treatment of these patients
Read moreAccording to a study led by the Institut de Neurociències of the UAB, Osanetant decreases the intensity with which the memory of fear is consolidated, thus preventing the onset of post-traumatic stre...
Read moreInvestigadores del Centro Nacional de Investigaciones Oncológicas (CNIO) han diseñado un fármaco ‘teragnóstico’, que se utiliza para imagen médica y también, con una mínima modificación, p...
Read moreThe phase 3 clinical trial KEYNOTE-689 shows that incorporating the monoclonal antibody pembrolizumab before and after surgery, alongside standard of care, improves event-free survival in patients wit...
Read moreThe targeted inhibitor ‘Zongertinib’ obtains positive responses in more than 70% of patients treated with this drug.
Read more